|Awarded On||August 24, 2018|
|Title||A Novel Anti-BCR-ABL Approach for Leukemia Therapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Hai Rao|
Our long-term goal is to elucidate the function of proteasome-mediated protein degradation in health and diseases. The goal of this proposal is to develop small molecules that would promote rapid degradation of BCR-ABL, a key factor in chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). Specifically, we will design and evaluate novel compounds that exploit the cell's own degradation pathway to eliminate the BCR-ABL protein kinase. Small molecules designed will bring BCR-ABL to the proteasome for destruction selectively. The study would lead to new anti-BCR-ABL drugs to CML and ALL patients. Our destruction-based approach significantly reduces the risk that acquired sec...